Epidermal growth factor receptor (EGFR)exon 19 deletion carriers of non-small cell lung cancer have so-called sensitized clonal lesions that respond well to tyrosine kinase inhibitors I.E. osimertinib, furmonertinib, and aumolertinib (Li et al., 2022). Here, EGFR is linked to non-small cell lung carcinoma.